Monday Sep 09, 2024

Day 04: Pedal to the metal on Road to the Max: Australia

Innovations in Medicine and Cutting-Edge Research in Melbourne

Day 04 of Road to the Max: Australia took us deeper into the heart of Melbourne’s life sciences sector, where we explored the innovations shaping the future of medicine and therapeutics. Our first stop was the Crown Plaza, where we met with Grant Swart, Australian General Manager of Mayne Pharma — a leading CDMO at the forefront of developing products across a variety of therapeutic areas, including cardiology, dermatology, oncology, and women’s health. Grant shared insights into Mayne Pharma’s mission to improve patient access to prescription medications by offering safer, better, and more accessible medicines.

Not All Heroes Wear Capes

After that, we headed to La Trobe University’s Institute for Molecular Science (LIMS), a hub of cutting-edge R&D. Here, we met Tim Oldham, CEO and Managing Director of AdAlta, a company pioneering a novel technology platform that engineers key stability features of shark antibodies into human proteins to create unique compounds known as i-bodies, which are designed for therapeutic intervention in disease, with an initial focus on treating fibrotic diseases. Day 04 was a testament to the groundbreaking work happening in Melbourne, where science and innovation are driving the future of healthcare. Stay with us as we continue our journey across Australia, uncovering the advancements that are changing lives.

Nelson Labs
NAS
Mayne Pharma
Curia
Continus
BVS
Alconox
AkDYS
AdAlta
Abzena
3Ci Aurigene
Aurigene
BSV
PI Health Sciences
Science 37
Reshaping the Approach to Therapeutic Development with i-Bodies

We met with Tim Oldham, Ph.D., CEO and Managing Director of AdAlta, on the campus of La Trobe University in Melbourne. Tim shares insights into AdAlta’s groundbreaking i-body platform, a next-generation human protein with superior abilities compared to traditional monoclonal antibodies. The i-body’s unique structure allows it to access grooves and cavities that other antibodies cannot reach, opening up new possibilities for treating debilitating diseases. Tim discusses how AdAlta is advancing therapeutic innovation and shaping the future of biotech.

Up close and personal with Brett Gooding.
"I'm scared, Fifi. You know why? It's that rat circus out there. I'm beginning to enjoy it."
A continental breakfast for our continental cruiser.
Gassed up and ready to ride.
Melbourne, here we come.
Mark is willing his beard to grow as long and majestic as Clint's.
Grant Swart, General Manager, Australia, at Mayne Pharma.
Downtown Melbourne is bustling at sunset.
The Interceptor isn't the only one in need of fuel.
Waterside art on a sunny day in Melbourne.
Mark and Nigel getting down to business.
Nothing but fun and games Down Under.
Have you seen this man?
Goose, Toecutter, Bubba Zanetti, and the Nightrider.
It's hard to look stoic when you're having so much fun in Australia.
Magic hour is approaching Melbourne.
Even Road Warriors need a sunrise yoga session.
Tim Oldham, CEO & Managing Director of AdAlta.